Fintel reports that on March 13, 2025, Citigroup initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) ...
Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...
Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...
BioNTech (BNTX) stock slid lower today after the German biotechnology company reported its Q4 2024 earnings. The company ...
Operator Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael ...
BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...
BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.
BioNTech's malaria vaccine trial faces an FDA clinical hold. The company is addressing concerns and collaborating with ...
BioNTech reported Q4 earnings of €1.08 per share, beating the €0.38 consensus but down from €1.88 last year. 2025 revenue guidance of €1.7B-€2.2B trails the €2.57B consensus.
Welcome to BioNTech's fourth quarter and full year 2024 earnings call. I would like to hand the call over to Michael Horowicz, director of investor relations. Please go ahead. Michael Horowicz ...